Methylphenidate hydrochloride (modified-release)
Brand: Methylphenidate MR
Overview
Medication class
Stimulant: methylphenidate hydrochloride (modified-release). Multiple UK brands available, each with a different release mechanism.
When it's prescribed
First-line treatment for ADHD in children aged 6 and over and adults, per NICE NG87. Must be prescribed and dispensed by brand name (MHRA guidance, September 2022).
Typical duration
8 hours (capsule brands) or up to 12 hours (tablet brands) from a single morning dose.
Available strengths
Varies by brand: from 5 mg to 60 mg capsules (Medikinet XL) and 18 mg to 54 mg tablets (Concerta XL and equivalents). See your brand's page for full details.
Key advantages
- Once-daily dosing: no midday top-up
- Multiple brands available to match different needs (duration, food requirements, swallowing ability)
- Capsule brands can be opened and sprinkled on cold food: useful if swallowing is difficult
- Well-established: the most extensively studied ADHD medication class
- Not pH-dependent (tablet brands): compatible with PPIs and antacids
Key cautions
- Brands are NOT interchangeable: always take the brand your prescriber prescribed
- Medikinet XL must be taken with food and is incompatible with PPIs and antacids
- Cardiovascular monitoring required before and throughout treatment
- Controlled drug (Schedule 2): stricter prescription rules
- Alcohol causes dose-dumping and forms ethylphenidate: avoid entirely
How it works
Your brain runs on chemical signals. Two of the most important for ADHD are dopamine and noradrenaline.
Dopamine gives tasks emotional weight: the motivation to start and keep going. Noradrenaline keeps your focus sharp and filters out background noise. With ADHD, both are in shorter supply in the key brain areas.
Methylphenidate blocks the brain's recycling transporters for these chemicals: keeping them available longer in the synapse. This isn't the same as amphetamines: methylphenidate slows the drain rather than turning up the tap.
**How the modified-release mechanism works:**
Tablet brands (Concerta XL and equivalents) use an osmotic pump: about 22% of the dose releases immediately; the remaining 78% is pushed out slowly over 6–7 hours through a tiny hole. The effect rises gradually through the morning. You may see a tablet shell in your stools; this is normal.
Capsule brands (Medikinet XL, Ritalin XL, Meflynate XL, Equasym XL) contain two types of pellets: immediate-release and modified-release: giving two overlapping peaks across 8 hours. The ratio differs by brand: Medikinet XL, Ritalin XL, and Meflynate XL are 50:50; Equasym XL is 30:70 (smaller first peak, larger second).
Capsule brands' coatings need stomach acid to work correctly: which is why PPIs and antacids are a problem for Medikinet XL specifically.
Methylphenidate hydrochloride blocks dopamine transporter (DAT) and noradrenaline transporter (NAT) in presynaptic neurons, reducing reuptake and increasing monoaminergic neurotransmission in prefrontal cortical circuits.
Tablet group (OROS mechanism): ~22% IR overcoat; ~78% delivered by osmotic push compartment via laser-drilled orifice. Produces ascending plasma profile over 12 hours. Not pH-dependent.
Capsule group (biphasic pellet): Two pellet populations: uncoated IR and polymer-coated MR pellets. Medikinet XL and Ritalin XL/Meflynate XL: 50:50 IR:MR. Equasym XL: 30:70 IR:MR. Peak plasma at ~1–2 h and ~4–5 h. pH-dependent: PPIs and antacids contraindicated with Medikinet XL specifically.
SPS bioequivalence groups (August 2025): Tablet group (Affenid XL, Atenza XL, Concerta XL, Delmosart, Matoride XL, Xaggitin XL, Xenidate XL): interchangeable within group. Capsule group (Focusim XL, Meflynate XL, Metyrol XL, Ritalin XL): interchangeable within group. Medikinet XL and Equasym XL: not freely interchangeable with other groups.
How to take it
When to take it
Once in the morning. As a rough guide, take it before 9am to avoid it still being active at bedtime.
With or without food
Depends on your brand. Medikinet XL must be taken with or after food; this is not optional. All tablet brands and Ritalin XL / Meflynate XL can be taken with or without food. Check your brand's page for the exact rule.
Tablets: swallow whole
Concerta XL, Affenid XL, Xaggitin XL, Xenidate XL, and Delmosart must be swallowed whole. Do not crush, cut, or chew them; this destroys the release mechanism and delivers the full dose at once.
Capsules: swallow or sprinkle
Capsule brands (Medikinet XL, Ritalin XL, Meflynate XL, Equasym XL) can be swallowed whole or opened and the pellets sprinkled onto cold soft food such as yoghurt or applesauce. Cold food only. Eat immediately. Never crush or chew the pellets.
Missed dose
If it is still morning, take it as soon as you remember. If it is already mid-afternoon, skip it and take the next dose tomorrow. Do not double up.
Alcohol
Avoid entirely. Alcohol can cause the modified-release mechanism to fail, releasing the full dose rapidly (dose-dumping). It also chemically reacts with methylphenidate to form ethylphenidate. Both carry risk.
Before surgery
Tell your surgeon and anaesthetist you take methylphenidate. You will usually be asked not to take it on the day of general anaesthesia. Check with your prescriber in advance.
MHRA September 2022: prescribe and dispense by brand name. Do not substitute without clinical review.
Medikinet XL: food required (affects absorption); PPIs, H2-blockers, and antacids contraindicated (pH-dependent release).
Concerta XL and tablet group: not pH-dependent; no food requirement; tablet shell in stools is normal.
Equasym XL: 30:70 release profile: standalone; no equivalent brand; do not switch without specialist review.
What to expect: week by week
Baseline checks
Your prescriber will check blood pressure, heart rate, weight, and relevant personal and family medical history before starting. Your prescription will name a specific brand: always make sure your pharmacy gives you exactly that one.
Adjustment
Appetite will dip, especially in the afternoon. Headaches are common in week one: mostly from mild dehydration, so drink more water. You might feel slightly more alert or on edge. Sleep may be lighter. Most settle by week 2.
Settling in
Most early side effects should be reducing. You should notice clearer focus, better task initiation, and fewer hours lost to distraction. If medication works well for most of the day but wears off too early, don't assume you need a bigger dose: discuss with your prescriber first.
Optimising
You may still be titrating towards the ideal dose. The goal is the dose that manages your symptoms well enough, for long enough, with the fewest side effects. If on an 8-hour capsule brand and coverage isn't lasting the whole day, a 12-hour tablet brand or a small IR top-up may be considered.
Maintenance
Once your dose is stable, reviews move to every 6 months. Blood pressure, heart rate, and weight are checked at each visit.
Treatment review
After a year, your prescriber may suggest a supervised treatment break: to check whether the medication is still needed and whether the dose is still right.
Side effects & what helps
All expanded by default: tap a category to collapse it. Most of these ease in the first 1–2 weeks.
Reduced appetite: especially through the afternoon; weight loss with long-term use
Very common (more than 1 in 10)What helps
Eat a proper breakfast before your dose. Appetite usually returns in the evening: plan a good meal then. Monitor weight at reviews.
Nausea, stomach pain, dry mouth, indigestion
Common (up to 1 in 10)What helps
Usually settles within the first 1–2 weeks. Taking with food can help with nausea.
Difficulty falling asleep: especially if taken too late
Very common (more than 1 in 10)What helps
Take as early as practical. If still disrupted after 4 weeks, discuss with your prescriber: timing or brand may need adjusting.
Waking earlier than usual; lighter sleep
Common (up to 1 in 10)What helps
Wind-down routine from 9pm; avoid caffeine after midday.
Increased heart rate and blood pressure; palpitations
Common (up to 1 in 10)What helps
A modest rise is expected and monitored at every review. Contact your prescriber if resting HR is consistently above 100 bpm.
Raynaud's phenomenon: fingers or toes going pale or cold
Very rareWhat helps
Contact your prescriber.
Anxiety, irritability, low mood or emotional flatness
Common (up to 1 in 10)What helps
Worsening mood after starting or increasing dose should be reported promptly: not left until the next review.
Suicidal thoughts
Uncommon (up to 1 in 100)What helps
Contact your prescriber or crisis support immediately.
Psychosis symptoms (hallucinations, paranoia); mania
Uncommon/RareWhat helps
Stop and seek urgent review.
Headache: usually settles by week 2
Very common (more than 1 in 10)What helps
Drink more water: usually just mild dehydration.
Dizziness, tremor, tiredness
Common (up to 1 in 10)What helps
Don't drive while dizzy. Mention at next review if persistent.
Tics: appearing or worsening
Rare (up to 1 in 1,000)What helps
Tell your prescriber before starting if you have a history of tics or Tourette's. Contact prescriber if tics appear or worsen.
Sweating, hair thinning, teeth grinding, decreased sex drive
Common (up to 1 in 10)What helps
Mention at next review if troublesome.
Priapism (painful erection lasting more than 2 hours)
Rare: medical emergencyWhat helps
Attend A&E immediately.
When to seek help
Monitor at home: mention at next review
Expected effects in the first few weeks
- Reduced appetite, stable and gradually improving
- Mild headache in weeks 1–2
- Dry mouth, thirst
- Mild sleep difficulty: try taking dose 30 minutes earlier
- Mild irritability that is already improving
- Tablet shell visible in stools (tablet brands): completely normal
Contact your prescriber within a few days
Not urgent: but worth discussing
- Resting HR consistently above 100 bpm, or ongoing palpitations
- BP persistently raised above your usual readings
- Headaches lasting beyond 2 weeks
- Mood changes, anxiety, or irritability not settling at 4 weeks
- Sleep severely disrupted beyond 4 weeks
- Significant or rapid weight loss
- Tics appearing or worsening
- Blurred vision; Raynaud's symptoms
Contact prescriber or 111 today
Do not wait for a routine appointment
- Resting HR above 120 bpm; BP significantly raised; fainting
- Suicidal thoughts or thoughts of self-harm
- Hallucinations, severe paranoia, or other psychotic symptoms
- Severe allergic reaction: facial swelling, difficulty breathing, widespread rash
- Priapism: painful erection lasting more than 2 hours (also attend A&E)
- New mania symptoms
- Severe abdominal pain
What you can safely try while waiting for a review
- Headache: drink more water; avoid caffeine after midday
- Appetite: eat breakfast before your dose; keep nutritious snacks for the evening
- Sleep: take your dose 30 minutes earlier; avoid screens after 10pm
- Anxiety: track whether worse on dose days vs off days: helps your prescriber
- Dry mouth: sugar-free gum; frequent small sips of water
Frequently asked questions
Ask your prescriber
Questions worth raising at your next review. You don't need to cover all of them: pick the ones that feel most relevant.
- Which brand have you prescribed for me: and why that one?
- What dose are we starting at, and what is the maximum?
- How long before we know if this dose is right?
- Do I need to take it with food? Can I open the capsule if I struggle to swallow?
- What if my pharmacy can't get my specific brand?
- Which side effects should I call you about rather than wait?
- What blood pressure and heart rate numbers would concern you?
- I take [list medications: especially acid-suppression drugs, antidepressants, or BP medications]: are any of these a concern?
- I have a history of tics: does that change anything?
- If this brand doesn't work well enough, what would we try next?
- How long will I stay on this, and will there be a planned treatment break?
- I travel abroad: what do I need to know about carrying a Schedule 2 prescription?
For GPs & clinicians
Methylphenidate MR products must be prescribed and dispensed by brand name. Products have clinically different pharmacokinetic profiles: different IR:MR ratios, mechanisms, food requirements.
SPS bioequivalence groups (August 2025): - 12h tablet group (interchangeable within group if needed): Affenid XL, Atenza XL, Concerta XL, Delmosart, Matoride XL, Xaggitin XL, Xenidate XL - 8h capsule group (interchangeable within group with care): Focusim XL, Meflynate XL, Metyrol XL, Ritalin XL - Medikinet XL: switches possible but need care: not fully bioequivalent with capsule group; food requirement applies - Equasym XL: no equivalent: do not switch without specialist review
Cross-group switches always require clinical review and dose reassessment.
Note on individual variation: Bioequivalence describes population-average pharmacokinetic equivalence. Individual patients may report meaningful differences in efficacy, side effect profile, or duration between brands within the same bioequivalence group. Patient reports of a difference after a brand switch should not be dismissed. Where supply allows, prescribing the patient's preferred brand within their bioequivalence group is appropriate.
Methylphenidate MR is not formally licensed for adults in the UK (BNF). However, NICE NG87 recommends methylphenidate as first-line for adults alongside lisdexamfetamine. Use under specialist direction is accepted UK practice. Shared care does not transfer clinical responsibility from the initiating specialist.
BP and HR at baseline, each dose change, and minimum every 6 months. Weight at each review. Screen for personal and family cardiac history before initiation.
Thresholds for action: resting HR >100 bpm: review dose before increasing; systolic BP >140 or diastolic >90 mmHg: review before dose increase. Consider ECG if personal or family history of arrhythmia or structural heart disease.
MAOIs: contraindicated; 14-day washout required. Alcohol: ethylphenidate formation (CES1A1 pathway) + dose-dumping risk with MR formulations. PPIs/H2-blockers/antacids: contraindicated with Medikinet XL specifically (pH-dependent release); not an issue for tablet brands. Antihypertensives: methylphenidate may reduce antihypertensive efficacy; monitor BP. Coumarin anticoagulants: methylphenidate may inhibit CYP2C9; monitor INR. TCAs/SSRIs/SNRIs: serotonin syndrome risk; use with caution. Alpha-2 agonists (clonidine, guanfacine): combination used in ADHD; requires monitoring.
Pregnancy (BUMPS/UKTIS January 2023): Not clearly teratogenic at therapeutic doses; small increased risk of cardiac defects in early pregnancy cannot be excluded; potential for fetal growth restriction; neonatal adaptation syndrome possible near delivery. Do not advise abrupt discontinuation. Individual risk-benefit discussion with specialist, obstetrician, and patient.
Breastfeeding (BfN April 2025): Methylphenidate is the stimulant of choice during breastfeeding. RID very low. Women do not need to stop breastfeeding. Advise: lowest effective dose; time doses after a feed; monitor baby for irritability, sleep changes, feeding difficulties.
This guide is written for educational purposes and does not constitute medical advice. Always follow the guidance of your prescriber or pharmacist. If you have concerns about your medication, contact your clinical team.